Eledon Pharmaceuticals Inc (ELDN) Stock Price, Quote & News

Company Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 238 8090

Website: eledon.com

Address:

19800 MacArthur Boulevard, Suite 250, Irvine, United States

MrCodyHUN Jul. 16 at 10:31 AM

$ELDN There is a chance for a bullish continuation toward $4.08–$4.20, but only if $3.90 breaks with volume. The price did jump to $4 in the AH, i'm positive. On the 1H frame, time is above VWAP, RSI is not overbought anymore, and the price is abover the BB midline. MACD is consolidating.

0 · Reply

MrCodyHUN Jul. 15 at 7:11 PM

$ELDN Big time consolidation

0 · Reply

Ontherag Jul. 15 at 5:02 PM

$ELDN This will continue to move up, and if your worried sell end of October

0 · Reply

Ontherag Jul. 15 at 5:02 PM

$ELDN As mentioned at R$D day, top line readout for Bestow trial is early Nov, less than 4 months.

0 · Reply

MRB250 Jul. 15 at 3:19 PM

$ELDN if it dips to 3.50 may buy in for a bounce

0 · Reply

MrCodyHUN Jul. 15 at 2:38 PM

$ELDN Next target is to claim 3.85. If that happens, another climb to 4.09

0 · Reply

MrCodyHUN Jul. 15 at 2:22 PM

$ELDN Key support at 3.7, needs to be intact.

0 · Reply

SlayQueenOfCalls Jul. 14 at 11:42 PM

$ELDN naturally because I sold too early ffs. You’re welcome my peeps

1 · Reply

MrCodyHUN Jul. 14 at 4:25 PM

$ELDN new high of the day

1 · Reply

MrCodyHUN Jul. 14 at 4:18 PM

$ELDN Recently invested, looking for breaking the 4.5 range in the following days. The company itself looks really groundbreaking.

0 · Reply

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

May 14, 2025, 4:01 PM EDT - 2 months ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 6, 2025, 1:15 PM EDT - 2 months ago

Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +

GEVO IRDM LPG

May 3, 2025, 8:15 AM EDT - 2 months ago

Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet

Mar 20, 2025, 4:01 PM EDT - 4 months ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 4, 2025, 4:05 PM EST - 4 months ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Feb 7, 2025, 10:00 AM EST - 5 months ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Jan 29, 2025, 4:05 PM EST - 6 months ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 28, 2025, 11:27 AM EST - 6 months ago

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Jan 13, 2025, 7:00 AM EST - 6 months ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Nov 12, 2024, 4:01 PM EST - 8 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Oct 29, 2024, 3:51 PM EDT - 9 months ago

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29, 2024, 7:46 AM EDT - 9 months ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:45 AM EDT - 9 months ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Sep 11, 2024, 4:05 PM EDT - 11 months ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 4, 2024, 7:00 AM EDT - 11 months ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Aug 14, 2024, 5:21 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Jun 3, 2024, 4:01 PM EDT - 1 year ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

May 9, 2024, 7:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 7, 2024, 7:05 AM EDT - 1 year ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Mar 28, 2024, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 25, 2024, 4:56 PM EDT - 1 year ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 21, 2024, 10:31 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Feb 13, 2024, 7:01 PM EST - 1 year ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 4, 2024, 4:40 PM EST - 1 year ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Nov 29, 2023, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Nov 9, 2023, 4:01 PM EST - 1 year ago

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Nov 8, 2023, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Nov 2, 2023, 9:05 AM EDT - 1 year ago

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Oct 23, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Oct 13, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Oct 2, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Sep 25, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

Sep 20, 2023, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference

May 12, 2023, 1:03 PM EDT - 2 years ago

Eledon Pharmaceuticals, Inc. (ELDN) Q1 2023 Earnings Call Transcript

May 10, 2023, 2:45 PM EDT - 2 years ago

Eledon Pharmaceuticals: Disrupting The Kidney Transplantation Landscape

Mar 31, 2023, 6:00 AM EDT - 2 years ago

Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

Mar 30, 2023, 8:28 PM EDT - 2 years ago

Eledon Pharmaceuticals, Inc. (ELDN) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results

Mar 23, 2023, 4:05 PM EDT - 2 years ago

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023

Feb 8, 2023, 4:05 PM EST - 2 years ago

Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

Jan 9, 2023, 8:31 AM EST - 2 years ago

Eledon Pharmaceuticals Provides Business and Pipeline Updates

Dec 21, 2022, 4:05 PM EST - 2 years ago

C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

MrCodyHUN Jul. 16 at 10:31 AM

0 · Reply

MrCodyHUN Jul. 15 at 7:11 PM

$ELDN Big time consolidation

0 · Reply

Ontherag Jul. 15 at 5:02 PM

$ELDN This will continue to move up, and if your worried sell end of October

0 · Reply

Ontherag Jul. 15 at 5:02 PM

$ELDN As mentioned at R$D day, top line readout for Bestow trial is early Nov, less than 4 months.

0 · Reply

MRB250 Jul. 15 at 3:19 PM

$ELDN if it dips to 3.50 may buy in for a bounce

0 · Reply

MrCodyHUN Jul. 15 at 2:38 PM

$ELDN Next target is to claim 3.85. If that happens, another climb to 4.09

0 · Reply

MrCodyHUN Jul. 15 at 2:22 PM

$ELDN Key support at 3.7, needs to be intact.

0 · Reply

SlayQueenOfCalls Jul. 14 at 11:42 PM

$ELDN naturally because I sold too early ffs. You’re welcome my peeps

1 · Reply

MrCodyHUN Jul. 14 at 4:25 PM

$ELDN new high of the day

1 · Reply

MrCodyHUN Jul. 14 at 4:18 PM

$ELDN Recently invested, looking for breaking the 4.5 range in the following days. The company itself looks really groundbreaking.

0 · Reply

jshlam Jul. 14 at 4:04 PM

$ELDN still down on the 6 month chart, this is gonna fly with the end of the year

1 · Reply

SlayQueenOfCalls Jul. 14 at 3:11 PM

$ELDN this was fun! I’m out for now - great day!

0 · Reply

Veraton Jul. 14 at 2:47 PM

$ELDN we should start getting 500-1.000.000-2.000.000-3.000.000 volume days Things will start to move fast this second semester Massive!!!!!

0 · Reply

jshlam Jul. 14 at 1:47 PM

$ELDN volume is really high

1 · Reply

SlayQueenOfCalls Jul. 13 at 9:51 PM

$ELDN she is oddly green a lot of times for my $5 calls

0 · Reply

MileHighAC92 Jul. 13 at 5:33 PM

$ELDN this is a momentum play I’m making, buy limit set for $3.30. Sell 50% at $4, sell remaining 50% at $5. Equals 27% upside

0 · Reply

StreetwiseReports Jul. 10 at 7:54 PM

Canadian Biotech Targets Massive Cell Technology Gains https://ow.ly/UBig50Wo04u Sernova Biotherapeutics Inc. recently announced a partnership with Eledon Pharmaceuticals Inc. to explore the utility of Eledon's clinical-stage anti-CD40L monoclonal antibody tegoprubart/AT-1501 for conferring sustainable immune evasion of pancreatic islets deployed into Sernova's Cell Pouch device. Read on to see why one Leede Financial Inc. analyst rates this stock as a Speculative Buy. $SVA.V $SEOVF $ELDN

0 · Reply

Veraton Jul. 10 at 4:27 PM

$ELDN theres no ask size... Only peanuts,,, as soon all of these intermediaries for funds that participated in yesterdays panel star throwing money in from investors this will sky rocket....

0 · Reply

jshlam Jul. 10 at 2:34 PM

$ELDN volume dried up

0 · Reply

Channelchek Jul. 10 at 12:43 PM

Noble Capital Markets Research Report: Eledon Pharmaceuticals ($ELDN) – Meeting Highlights Tegoprubart Data Milestones and New Indications R&D Day Highlighted Science, Current Trials, Future Indications. We attended the Eledon R&D Day on July 9 to hear and evaluate the progress in tegoprubart development. The presentations focused on the current clinical indications in renal transplantation, islet cell transplantation, xenotransplants, and plans for liver and other solid organ transplants. Conference presentation dates for upcoming data announcements were also announced. Read more: https://www.channelchek.com/news-channel/eledon-pharmaceuticals-eldn-meeting-highlights-tegoprubart-data-milestones-and-new-indications

0 · Reply

Veraton Jul. 10 at 12:23 PM

$ELDN what i saw yesterday in that panel gave me a lot of confidence.... Im doubling down hard!!!!

0 · Reply

jshlam Jul. 9 at 11:16 PM

$ELDN got to do closing bell today

0 · Reply

Market Cap	234.14M
Revenue (ttm)	0.00
Net Income (ttm)	-36.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	519,150
Avg Vol	448,080
Day's Range	N/A - N/A
Shares Out	59.88M
Stochastic %K	82%
Beta	-0.16
Analysts	Strong Sell
Price Target	$9.00